The drug candidate is datopotamab deruxtecan, an experimental therapy for locally advanced or metastatic non-small cell lung cancer in patients who have been treated with another chemotherapy — such as docetaxel, the standard treatment that is in short supply.
In a news release, AstraZeneca said the study will “continue as planned to assess overall survival with greater maturity.” No new safety concerns were noted in the phase 3 trial, and “some Grade 5 events [deaths] were observed.”
The candidate met its endpoint of progression-free survival.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
